Loading news...
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month
Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026. “Building on the progress we achieved in our RSV and immunology portfolios this past year, we enter 2026 with strong momentum as we continue to expand our pipeline and deliver.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enanta's President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the event will.
Enanta Pharmaceuticals (ENTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The consensus price target hints at a 44.9% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Enanta Pharmaceuticals (ENTA) remains a "Buy" due to promising secondary endpoints for zelicapavir in RSV, despite missing its primary endpoint. Company's pipeline strength is supported by EDP-323's positive prophylaxis data and robust preclinical immunology programs targeting STAT6 and KIT pathways. The company's strong cash position, now extended into fiscal 2029 after a recent equity raise, ensures continued development of its clinical programs.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025. “This past quarter marked a pivotal period for Enanta, with significant progress across our virology and immunology programs, highlighted by positive topline data from the RSVHR study, our Ph.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December. Jefferies London Global Healthcare Conference: Fireside Chat on Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET 8th Annual Evercore Healthcare Conf.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that new data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, its oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 – 22,.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it's oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 - 22, 20.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has closed its previously announced underwritten public offering of 7,475,000 shares of its common stock, which includes 975,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $10.0.
U.S. stock futures were lower this morning, with the Dow futures falling more than 200 points on Wednesday.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of custom.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its comm.
Enanta Pharmaceuticals, Inc. - Special Call Company Participants Jennifer Viera - Executive Director of Investor Relations & Corporate Communications Jay Luly - President, CEO & Director Scott Rottinghaus - Chief Medical Office Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Antonio Arce - WestPark Capital, Inc., Research Division Brian Skorney - Robert W.
Enanta Pharmaceuticals remains a Buy as zelicapavir shows multiple positive efficacy endpoints in RSV despite missing its primary endpoint in the phase 2b study. Zelicapavir demonstrated statistically significant improvements in PGI-S scores and viral load reduction, supporting potential for phase 3 advancement pending FDA feedback. Strong cash position funds operations into 2028, with ongoing MAVYRET/MAVIRET royalties and a manageable quarterly cash burn.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpatient adults with acute RSV infection who are at high risk of complications including the elderly and/or those with.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast.